(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 1,262.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Inovio Pharmaceuticals's revenue in 2026 is $65,343.On average, 7 Wall Street analysts forecast INO's revenue for 2026 to be $1,106,438,583, with the lowest INO revenue forecast at $0, and the highest INO revenue forecast at $3,012,132,914. On average, 5 Wall Street analysts forecast INO's revenue for 2027 to be $4,773,217,780, with the lowest INO revenue forecast at $2,302,351,250, and the highest INO revenue forecast at $8,878,316,346.
In 2028, INO is forecast to generate $12,201,639,430 in revenue, with the lowest revenue forecast at $8,199,833,338 and the highest revenue forecast at $14,747,678,008.